

Series A: \$10M+ | Strategic Investors

Perfect vision at every distance.

Autofocusing eyewear that restores natural sight.
Creating the next global standard in vision correction.



Endgame: Own an emerging category

We are not just making better glasses.
We're setting a new standard of vision care.



DEFINE & OWN THE CATEGORY

Establish "Autofocusing Eyewear" as a distinct market segment.

BECOME THE NEW GOLD STANDARD

Replace multifocals and progressives for presbyopia care.

STRATEGIC EXPANSION

Consumer eyewear → Medical applications →
Licensed vision intelligence.

THE PROBLEM

A \$30B market. A 70-year-old solution.


Our eyes lose the ability to focus on nearby and intermediate objects as we age – **this is presbyopia**. It's inevitable and universal, and it begins at the height of our productive lives.

2.1B

People with presbyopia by
2030 (1.8B today)

\$30B/yr

Current EU + US spend on
progressive glasses



\$90B/year

Unmet demand for a better solution

The market exists.
The pain is real.

The current solutions are failing it.

\$30B current market × **3–10x** new standard-of-care growth multiplier → **\$90B/yr+**
Leaders with IP & differentiation capture **40–70%** long-term share.

Biologically inevitable. 100% of people are affected by 60+.
No cure exists - only management.
The condition worsens across the highest-earning decades of people's lives.

8x more difficulty in demanding near-vision tasks for the uncorrected - career-limiting for surgeons, engineers, architects, dentists, researchers, etc. (Systematic Review, 2020).

People adapt to the glasses. Not the other way around.

Progressives have been the global standard for decades.
Every flaw listed here shipped with the original.

1 in 3

Falls in 70+ adults are
linked to progressive lens
distortion*

150M+

Precision workers have
no viable solution to
continue their craft



The adaptation burden. Progressives require users to tilt their head, hunt for sweet spots, and train their posture and gaze — every day, for life. Chronic eye strain and neck strain are built in. The higher the prescription, the harder the adaptation due to reduced in-focus areas on the lens itself.

1 in 3 falls in adults over 70 are linked to peripheral distortion from progressive lenses — up to \$100K per incident in medical costs. This safety failure is a progressive product feature.

20% never adapt at all. A fifth of advanced presbyopes cannot use progressives effectively — 150M+ people in precision professions are left without a working path forward by the current standard of care.

No solution today delivers continuous,
effortless vision at all distances.

The gap is structural — and it's been structural for seven decades.

Autofocals[®]

Autofocusing glasses that dynamically adjust focus in real time, restoring perfect vision at every distance.

Video of Users

INSTANTANEOUS & AUTOMATIC REFOCUSING

Imperceptible adjustments < 100ms.
No buttons, no dials, no effort.

FULLY RESTORED VISUAL ACUITY

Restores the eye's natural accommodation ability equivalent to age 20.

SEAMLESS EVERYDAY USE

Instantly transition between reading, computer work, and outdoor activities.



Near

Intermediate

Far

Viewing distance

15"

45"

INFINITY

Core Technology



DUAL INWARD CAMERAS

Miniaturized, high-frame-rate sensors positioned discreetly to capture subtle eye movements.

END TO END LENS OPTIMIZATION & MANUFACTURING

Software enabling custom-designed lenses with variable focal power to match prescriptions.

PROPRIETARY AI

- Precise pupil detection.
- Real-time eye tracking.
- Depth-of-gaze estimation.

CUSTOM ELECTRONICS

Electronics, firmware, and power management systems optimized for all-day wearability.

[Our Patents 01](#)

[Our Patents 02](#)

<100MS RESPONSE

Closed-loop autofocus system reacting faster than human perception for seamless vision.

INTEGRATED FRAME

Ergonomic design concealing technology completely, indistinguishable from premium eyewear.



Benefits vs Existing Solutions

Category	Multifocals / Progressives	FULLER VISION
Visual Clarity	<div><div>✕</div><div>Compromised Zones Only "sweet spots" are clear</div></div>	<div><div>✓</div><div>Perfect at all distances</div></div>
Response Time	<div><div>⚠</div><div>Slow / Static Requires head adjustment</div></div>	<div><div>✓</div><div><100ms Instant Autofocus</div></div>
Spatial Awareness	<div><div>✕</div><div>Distorted Periphery Reduced balance & safety</div></div>	<div><div>✓</div><div>Natural Field of View</div></div>
Cognitive Load	<div><div>🔊</div><div>High Fatigue Brain compensates for blur</div></div>	<div><div>✓</div><div>Effortless Vision</div></div>
8		Fuller Vision



Why Now?

A convergence of hardware breakthroughs, AI capabilities, and demographic shifts creates the perfect window of opportunity.

MINIATURIZED OPTICS

High-fidelity cameras are finally small enough to fit inside standard eyewear frames.

EDGE AI EFFICIENCY

Real-time gaze and depth estimation is now possible on-device with whole-day power efficiency.

DEMOGRAPHIC DEMAND

People 55+ are increasingly demanding premium “quality-of-life” technology.

OUTCOME-BASED CARE

Vision care is shifting from static prescriptions to dynamic, restorative outcome-based solutions.

Why Us?

A multidisciplinary team with deep domain expertise, backed by the best medical professionals in the eye care industry.

THE 60+ SOLUTION

Only our technology addresses the acute vision needs of the high-pain 60+ demographic.

CLINICIAN-PARTNERED

We work with elite eye care clinicians to define the future standard of vision care.

BIOLOGY-INSPIRED AUTOFOCUS

Our intent engine instantly translates natural eye behavior into focus with zero user friction.

SEASONED TECH PIONEERS

After 7 years of R&D, we have productized “impossible” technology and are now conducting real-world demos.

Market Response

Institutional partnerships and commercial interest validate both the clinical need and market demand for Autofocals.



CLINICAL & INSTITUTIONAL

—
KAISER PERMANENTE — LOI

Field-test agreement with California's largest integrated health network. First institutional real-world deployment.

—
WILLS EYE HOSPITAL — PARTNERSHIP

Strategic partnership with one of the world's leading ophthalmology institutions, Philadelphia. Clinical credibility and referral access.

COMMERCIAL

500+

Preorders & growing
\$3,000 MSRP pilot price

8

Optometrist distributors
Secured across US markets

Beachhead Customer

The Active Modern Senior

Gadget-friendly &
Quality-of-Life
Focused

Tech-Positive

Early Adopter

Professional

Health-Conscious



55+ Age Group

TARGET CONTEXT

Individuals with moderate to advanced presbyopia who refuse to slow down. They experience vision loss as a major barrier to their lifestyle.

Visually Demanding Work

Consultants, engineers, executives needing sharp focus.

Daily Movement

Active lifestyle requiring balance and spatial awareness.

Technical Hobbies

Photography, precision crafts, digital content creation.

Digital Natives

Comfortable with wearables and app-connected devices.

25M

INITIAL ADDRESSABLE MARKET (ICP)
High-income individuals with advanced presbyopia across the US & EU ready for a premium solution.

Scaling the Market

GLOBAL MARKET EXPANSION

Targeting the mass-affluent segment with advanced presbyopia needs across key global markets.

Top 50%

INCOME EARNERS GLOBALLY

DISTRIBUTION CHANNELS

PREMIUM OPTICAL RETAILERS

High-touch fitting experience for flagship customers and brand visibility.

DIRECT-TO-CONSUMER (DTC)

Maximizing margin and customer data ownership.

STRATEGIC PARTNERSHIPS

INSURERS

Coverage agreements to subsidize costs for medical-necessity use cases.

HEALTH SYSTEMS

Integration into geriatric care and post-surgery recovery protocols.

Monetization Streams

Hardware Sales

ONE-TIME PURCHASE

High-margin premium eyewear sales direct to consumer and through retail partners.

- Premium margin profile (>60%)
- High average order value (\$3,000 pilot MSRP)

Membership Model

OPTIONAL SUBSCRIPTION

Value-added services driving retention and lifetime value (LTV).

- Automatic hardware upgrades every 24 months
- Feature updates & cross-sell opportunities
- Extended warranty & premium support

Enterprise

B2B WHOLESALE

- Bulk contracts with insurers and health systems
- Subsidized patient care
- Employee wellness program

Data Licensing

RESEARCH ASSETS

- Monetizing anonymized eye-behavior datasets
- Medical research (Neuro)
- Opt-in patient cohorts

SaaS Platform

TECHNOLOGY LICENSING

- Proprietary lens optimization software
- Sold to lens manufacturers
- Recurring licensing fees

Market Opportunity


INITIAL TARGET (SOM)

High-income, advanced presbyopes with premium willingness to pay.



TOTAL ADDRESSABLE (TAM)

Global presbyopia population, focusing on the 50+ demographic in high-income economies.



MSRP and Product Evolution

PRICING SEGMENTATION

Pilot Phase (2026/27)
Single SKU (first 1,000 units)

\$3,000 MSRP

FEATURE ROADMAP

● 2026 / 2027

MARKET ENTRY

Core Autofocus Reliability
Consumer-grade Manufacturing

● 2028 Onwards

EXPANSION FEATURES

Fashion Styles & Frame
Variations Health Diagnostics
(Temp, Fatigue, Stroke)

Pricing Strategy
2027 Onwards

STARTER

\$2,000

Core Autofocus Reliability
Consumer-grade Manufacturing

- ✓ Core Autofocus
- ✓ Standard Frames

BEST SELLER

FLAGSHIP

\$4,000

Premium materials and
full diagnostic suite.

- ✓ Adv. Autofocus
- ✓ Premium Materials
- ✓ Fatigue Monitor

PREMIUM LUXURY

\$6,000

Designer collaborations &
exclusive materials.

- ✓ All Flagship Features
- ✓ Gold/Titanium
- ✓ Concierge Support
- ✓ Designer Brand

Neuro-Assistive Vision

PARKINSON'S DISEASE

Compensates for tremors by stabilizing the visual field, allowing for easier reading and fine-motor tasks.

ALZHEIMER'S & DEMENTIA

Reduces spatial confusion by enhancing contrast and clearly defining object boundaries in the user's environment.

MULTIPLE SCLEROSIS

Combats optic neuritis symptoms by providing instant, sharp focus adjustments to overcome blurred vision episodes.



Impact on Daily Life


- ✓ Improves daily function and independence for aging patients.
- ✓ Supports visually demanding tasks despite neurological decline.
- ✓ Reduces cognitive load required to process visual information.

LONG-TERM GOAL

Become the standard-of-care assistive vision device for chronic illness relief.

Vision Telemetry Platform

INPUT



Continuous Collection

Passive monitoring of eye movements during natural daily behavior.



PROPRIETARY SIGNALS

GAZE STABILITY

Micro-saccade detection and fixation capability analysis.

REACTION TIME

Oculomotor response latency to visual stimuli.

FATIGUE LEVELS

Blink rate variability and eyelid closure duration.

NEURO MARKERS

Pupillary light reflex and complex tracking patterns.



CLINICAL VALUE

01

Early Diagnosis

Detecting subtle neuro-degenerative signs before clinical symptoms appear.

02

Disease Monitoring

Quantitative tracking of progression for Parkinson's & MS.

03

Therapy Tracking

Measuring objective effectiveness of drug or physical therapies.

Creating a high-value, longitudinal data layer unique to autofocusing eyewear.



Competitive Landscape

Status Quo

Multifocals / Progressives

- ✗ Static lenses with optical compromises
- ✗ Limited field of view
- ⚠ Requires head tilting and adaptation period
- ✓ The best selection of frame options

Autofocus Rivals

Early Market Entrants

- 📺 Early Market Entrants
Limited reading add (+1.0 to +1.5D)
- 👁 Fresnel lens limitations (ghosting & partial focus area)
- ⬆ Binary focus: Only Near and Far (No Mid-distance)
- ✓ Slightly more elegant frame options vs Autofocals

CATEGORY LEADER

Fuller Vision

The New Standard

- ✓ **Fully personalized +3.0 Reading Add** Up to +/- 5 diopters distance correction
- ✓ **Real-time Autofocus** Continuous clarity at Near, Mid, and Far
- 🕒 Full proprietary stack: Lens + AI + Software integration
- 🛡 High barriers to replication (IP & Data)



Defensibility & Moat

01

PROPRIETARY AI EYE-TRACKING

Advanced algorithms for pupil detection and depth-of-gaze estimation optimized for low-power edge computing.

02

LENS OPTIMIZATION SOFTWARE

Custom software stack enabling variable focal power adjustments with sub-100ms response times.

03

INTEGRATED CO-DESIGN

Tightly coupled hardware, software, and optics architecture that is difficult to reverse-engineer.

04

BEHAVIORAL DATA ASSET

Accumulating the world’s largest dataset of real-world eye behavior and neurological signals.

05

CLINICAL & REGULATORY VALIDATION

First-mover advantage in clearing medical device pathways for active focus correction.

06

CATEGORY OWNERSHIP

Establishing Fuller Vision as the synonym for “Autofocals,” creating lasting brand equity.

Roadmap & Expansion

2026

FOUNDATION & LAUNCH

Product Reliability

Finalize consumer-grade durability testing and validation.

Manufacturing Scale

Establish supply chain partners for lens, electronics and frame assembly.

Commercial Pilot

Secure 1,000 preorders and deploy first units.

2027

GROWTH & ECOSYSTEM

Strategic Pilots

Launch programs with optical partners and health insurers.

Medical Trials

Initiate clinical studies for neurodegenerative use cases.

Market Traction

10,000 units sold and lens optimizer SaaS licensing launched.

GEOGRAPHIC
ROLLOUT

2027 UNITED STATES

2028 EUROPEAN UNION

2030 ASIA PACIFIC

P&L 2026-2031



Category	2026	2027	2028	2029	2030	2031	Total 2026 - 2031
Salaries	\$1,028,848	\$7,611,195	\$50,706,242	\$245,032,872	\$807,287,058	\$1,959,094,736	\$3,070,760,951
Manufacturing line	\$590,000	\$0	\$120,000	\$1,320,000	\$4,940,000	\$7,590,000	\$14,560,000
IP protection costs	\$13,333	\$60,000	\$120,000	\$170,000	\$240,000	\$240,000	\$843,333
Offices and business support	\$202,128	\$535,662	\$679,270	\$827,314	\$970,625	\$1,217,262	\$4,432,261
Regulatory approval	\$200,000	\$900,000	\$700,000	\$400,000	\$0	\$0	\$2,200,000
Marketing and clinical education costs	\$141,000	\$7,235,591	\$74,851,989	\$394,876,491	\$1,328,933,677	\$3,245,827,171	\$5,053,315,937
Total operating costs	\$2,575,310	\$18,587,144	\$128,577,500	\$643,556,677	\$2,142,371,359	\$5,213,969,168	\$8,149,637,158
Total revenue	\$702,325	\$36,688,608	\$316,679,207	\$1,609,105,838	\$5,353,932,210	\$13,028,598,184	\$20,345,706,372
Total cost of sales (including unit production)	\$154,675	\$7,901,549	\$68,269,932	\$333,719,711	\$890,750,354	\$2,147,334,993	\$3,448,131,214
Gross profit	\$547,650	\$28,787,058	\$248,409,275	\$1,275,386,127	\$4,463,181,855	\$10,881,263,191	\$16,897,575,156
Net profit	-\$2,027,660	\$10,199,915	\$119,831,775	\$631,829,450	\$2,320,810,496	\$5,667,294,023	\$8,747,937,999
Net profit margin	-288.71%	27.80%	37.84%	39.27%	43.35%	43.50%	43.00%
Total number of units sold	230	11,750	114,369	604,018	2,032,786	4,964,936	7,728,089

Note: salaries and marketing cost growth in 2027 and onward is contingent on sales performance/revenue

Proxies and Competition



PROXIES						
Company	Launch → Exit	Raised	Valuation	Product & Channel	U.S. TAM / SAM (at Launch)	Hardware Gross Margin
Warby Parker	2010 → 2021 IPO	~\$540M	\$3B (IPO)	Fashion eyewear, sold online + stores	\$40B eyewear / ~\$3B online Rx glasses	~58–60%
Fitbit	2007 → 2015 IPO → 2021 acquired	~\$560M	\$2.1B (exit)	Fitness tracker, DTC + retail	\$70B wearables / ~\$4B fitness bands	~44–48%
Peloton	2012 → 2019 IPO	~\$1,900M	\$8.1B (IPO)	Connected bike + \$44/mo content	\$35B home fitness / ~\$4B premium bikes	~40–43% HW / ~65–70% blended
Eargo	2010 → 2020 IPO	~\$205M	\$1.4B (IPO)	Invisible hearing aids, fully online	\$9B OTC aids / ~\$1.5B mild-loss OTC	~56–58%
Whoop	2012 → 2021 acquired	~\$403M	\$3.6B (post)	Subscription fitness band	\$70B wearables / ~\$6B performance market	~50–55% HW / ~75% subs
Oura	2013 → 2022 acquired	~\$350M	\$2.6B (post)	Smart sleep ring, DTC only	\$10B sleep market / ~\$1B smart-ring	~52–55% + \$6/mo subs
Align Tech (Invisalign)	1997 → 2001 IPO	~\$280M	\$50B+ peak	Clear aligners via dentists	\$18B orthodontics / ~\$4B adult mild/mod cases	~75–78%
Dexcom	1999 → 2005 IPO	~\$62M	\$44B peak	Continuous glucose monitors (CGM)	\$25B diabetes tech / ~\$3B U.S. CGM	~63–66%
Insulet	2000 → 2007 IPO	~\$210M	\$20B today	Omnipod tubeless insulin pump, Rx only	\$7B insulin pumps / ~\$2B patch market	~65–68% disposables
iRhythm	2006 → 2016 IPO	~\$165M	\$8B peak	14-day ECG patch via cardiologists	\$3B cardiac monitors / ~\$1B ambulatory ECG	~71–74%
Glaukos	2001 → 2015 IPO	~\$156M	\$10B peak	iStent for glaucoma, prescribed surgically	\$4B glaucoma surgery / ~\$700M MIGS	~84–85%

COMPETITION						
Startup	Investors	Raised	Stage	Differentiator	U.S. TAM / SAM (at Launch)	Hardware Gross Margin
Fuller Vision	Kevin Mahaffey, D Moonshots	~6M	Preorders	Autofocus, custom prescription	\$40B eyewear / ~\$10B multifocal glasses	~90%
LaClaree	HTGF, UI-Investissement, Rimonci, EIC	~7M	Development		//	~85%
Morrow	ZEISS, NSV, PMV, Tokai, imec	~25M	On the market	Custom prescription, under 60yr	//	~90%
IXI	Plural, Amazon Alexa, Tesi, Heartcore	~44M	Development	Autofocus, under 60yr	//	~90%
Deep Optics	EssilorLuxottica, Fielmann, Samsung	~34M	On the market	Sunglasses, under 60yr	//	~85%



Nebojša Šabović
Co-Founder and
CTO



Reed Foster
Co-Founder and
CEO



Kevin Mahaffey
Business Advisor



Helen Vasilevski
Sales and Marketing
Advisor

We've assembled a team
of experts who share our vision
to help people see better.

Dr. Jason Dimmig
Dr. Robert Sergott

Dr. Michael D. Le
Dr. Clifford Lee

Meet the whole [Fuller Vision Team](#)

Funding Ask


\$10M
Direct equity

Enables:
30-month runway,
going at maximum speed

Ideal investor profile

Hardware, deep tech, health tech, wearables,
med tech, semiconductors

Investment
goes to:



Personnel
costs



Manufacturing
line setup



IP protection + offices &
business support



Sales and
marketing

Outcome:

\$315M

Annual revenue at the end of 2028

100k+
Units sold

Contact us for
more info



Reed Foster
reed@fuller.vision

Nebojša Šabović
neb@fuller.vision

